Navigation Links
HFSP research funding for the Helmholtz Zentrum München
Date:3/27/2014

The Human Frontier Science Program (HFSP) funds innovative research work in the field of life sciences. The organization's members are Australia, Canada, France, Germany, Great Britain, India, Italy, Japan, New Zealand, Norway, South Korea, Switzerland and the USA, as well as the EU. Research grants are awarded to international research collaborations that carry out interdisciplinary work in order to develop cutting edge approaches to fundamental issues in the life sciences.

Oxidized lipidomes: Key figures in non-apoptotic cell death

Oxidative modifications of lipids are a key process in non-apoptotic cell death signalling and play important roles in a number of relevant diseases, such as neurodegeneration, diabetes and asthma. A team of scientists headed by Dr. Marcus Conrad from the Institute of Developmental Genetics (IDG) at the Helmholtz Zentrum Mnchen (HMGU) now strives to intensify research into the underlying molecular mechanisms. The overall goal of this program is to identify the specific signature of oxidized lipids and to decipher the interaction of these modified lipids with signal molecules that ultimately promote non-apoptotic cell death. Knowledge gained by this approach should lead to the development of a language code that, in turn, may provide cues for the design of novel treatment strategies. The partners in the project are Dr. Valerian Kagan, University of Pittsburgh (USA), Dr. Fulvio Ursini, University of Padova (Italy) and Dr. Judith Klein-Seetharaman, Warwick Medical School, Coventry (UK).

Mechanosensation: transmission and perception of neuronal stimuli

Movement and coordination must be modulated according to the environment. They are subject to permanent feedback from the perceived stimuli and adequate adaptive responses. With respect to the perceived signals, it is necessary to distinguish between external influences and self-generated stimuli a capability that makes highly differentiated motor sequences possible. The scientists headed by Dr. Hrnan Lpez-Schier from the Sensory Biology and Organogenesis (SBO) research unit at the HMGU want to uncover the underlying mechanosensation circuits and precisely characterize the involved nerve cells and genes. Partners in the project are Prof. Florian Engert, Harvard University (USA) and Dr. Ana Belen Elgoyhen, INGEBI-CONICET in Buenos Aires (Argentina).


'/>"/>

Contact: Press Office
presse@helmholtz-muenchen.de
49-893-187-2711
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related biology news :

1. UGA researchers explore function of cancer-causing gene
2. CASIS-sponsored research heads to space station aboard SpaceX-3
3. Distinguished researcher to speak at NJIT on preventing bone loss
4. Researchers present comprehensive roadmap of blood cells
5. Research produces strong evidence for a new class of antidepressant drugs
6. UT Southwestern ob/gyn researchers studying genetic factors in premature births
7. Researchers issue state-of-the-state on genetic-based testing & treatment for breast cancer
8. Deep ocean current may slow due to climate change, Penn research finds
9. NIH grants up to $28 million to group led by Scripps Research for work on ebola treatment
10. Heidelberg researcher awarded Animal Welfare Prize of the German Research Foundation
11. Jump start for frontier projects: The 2014 HFSP Research Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2017)... Research and Markets has announced the addition ... and Commercial Aspects" to their offering. ... Biomarkers play an ... for selection of treatment as well for monitoring the results. ... in modern medicine. Biochip/microarray technologies and next generation sequencing are ...
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... WEST LAFAYETTE, Indiana (PRWEB) , ... ... ... a division of Albany Molecular Research Inc. has further extended its industry ... sector. This service offers state-of-the-art cGMP techniques and methods for the ...
(Date:2/15/2017)... Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial ... full year ended December 31, 2016. ... we continued to demonstrate strong growth in our ... said Mihael H. Polymeropoulos, M.D., Vanda,s President and ... 2017 milestones underscores Vanda,s commitment to bringing important ...
Breaking Biology Technology: